Praxis Precision Medicines Posts Q3 GAAP Net Loss of $3.23 Per Share

John Kim

1 min read

Praxis Precision Medicines Posts Q3 GAAP Net Loss of $3.23 Per Share

Cash, cash equivalents and marketable securities totaled $1.3 billion on Sept. 30, compared with $926.1 million on Dec. 31, 2025.

By John Kim

Published Nov 10, 2026, 2:40 AM EST

A glass vial balances beside a steel weight on an ivory plinth / TokenPost.ai

Praxis Precision Medicines posted a GAAP net loss of $3.23 per basic and diluted share for the third quarter of 2026, while its cash, cash equivalents and marketable securities totaled $1.3 billion at quarter-end.

The company held $926.1 million in those assets on Dec. 31, 2025.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.